Drug intelligence / Profile preview

SRN-21

Development stage: Preclinical
Lead developer: Sirana Pharma
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

SRN-21 is a preclinical-stage antisense oligonucleotide (ASO) being developed by Sirana Pharma for the treatment of sarcopenia (age-related muscle loss). The therapeutic utilizes Sirana's proprietary Musk-Link platform, which involves conjugating the ASO to a muscle-targeting peptide to enhance delivery and uptake specifically in skeletal muscle tissue. By targeting genetic regulators of muscle mass, SRN-21 aims to inhibit muscle wasting and promote muscle growth, addressing the unmet medical need for pharmacological interventions in sarcopenia and other muscle atrophy conditions.

Beyond the preview

Go deeper on SRN-21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRN-21.

Explore the full profile